The CHAARTED trial investigated the long-term survival of patients with metastatic hormone-sensitive prostate cancer (HSPC) treated with androgen deprivation therapy (ADT) with or without docetaxel (Taxotere). This analysis focuses on 10-year overall survival (OS) stratified by disease volume and on-therapy prostate-specific antigen (PSA) levels at 6 months.
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial☆
Annals of Oncology | | A. Tripathi, Y. Chen, D.F. Jarrard, J.A. Garcia, R. Dreicer, G. Liu, M.H. Hussain, D.H. Shevrin, M. Cooney, M.A. Eisenberger, M. Kohli, E.R. Plimack, N.J. Vogelzang, J. Picus, M.A. Carducci, R.S. DiPaola, C.J. Sweeney
Topics: prostate-cancer, blood-cancer, chemotherapy, clinical-trials